[Cyclooxygenase 2 and colorectal cancer: therapeutic implications].
There is epidemiological evidence that suggests an inverse association between the consumption of non-steroidal anti-inflammatories (NSAIDs) and the risk of developing certain neoplasms. This association led to the identification of the therapeutic target of these drugs, cyclooxygenase type 2 (COX-2). Later studies have demonstrated that COX-2 is over-expressed in many malignant and pre-malignant lesions of different origins, among which are included colorectal neoplasms. This factor explains the beneficial effect observed with the use of classic NSAIDs and more recently, with selective COX-2 inhibitors (coxibs), in the treatment and/or prevention of several neoplasms.
Castells
Antoni
A
Servicio de Gastroenterología, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, Villaroel 170, 08036 Barcelona, Spain. castells@clinic.ub.es
Balaguer
Francesc
F
Gonzalo
Victòria
V
Castellví-Bel
Sergi
S
D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control / Q000601:surgery; D000236:Adenoma / Q000188:drug therapy / Q000201:enzymology / Q000517:prevention & control; D011125:Adenomatous Polyposis Coli / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000601:surgery; D000328:Adult; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control / Q000601:surgery; D003131:Combined Modality Therapy; D051546:Cyclooxygenase 2 / Q000502:physiology*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000502:physiology*; D011230:Precancerous Conditions / Q000188:drug therapy / Q000201:enzymology; D011379:Prognosis; D012306:Risk
D052246:Cyclooxygenase 2 Inhibitors; D009363:Neoplasm Proteins; D051546:Cyclooxygenase 2